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Abstract
Background Frailty and multimorbidity are common in type 2 diabetes (T2D), including
people <65 years. Guidelines recommend adjustment of treatment targets in people with
frailty or multimorbidity. It is unclear how recommendations to adjust treatment targets in
people with frailty or multimorbidity should be applied to different ages. We assess impli-
cations of frailty/multimorbidity in middle/older-aged people with T2D.
Methods We analysed UK Biobank participants (n= 20,566) with T2D aged 40–72 years
comparing two frailty measures (Fried frailty phenotype and Rockwood frailty index) and two
multimorbidity measures (Charlson Comorbidity index and count of long-term conditions
(LTCs)). Outcomes were mortality, Major Adverse Cardiovascular Event (MACE), hospita-
lization with hypoglycaemia or fall/fracture.
Results Here we show that choice of measure influences the population identified: 42% of
participants are frail or multimorbid by at least one measure; 2.2% by all four measures. Each
measure is associated with mortality, MACE, hypoglycaemia, and fall or fracture. The
absolute 5-year mortality risk is higher in older versus younger participants with a given level
of frailty (e.g. 1.9%, and 9.9% in men aged 45 and 65, respectively, using frailty phenotype)
or multimorbidity (e.g. 1.3%, and 7.8% in men with 4 LTCs aged 45 and 65, respectively).
Using frailty phenotype, the relationship between higher HbA1c and mortality is stronger in
frail compared with pre-frail or robust participants.
Conclusions Assessment of frailty/multimorbidity should be embedded within routine
management of middle-aged and older people with T2D. Method of identification as well as
features such as age impact baseline risk and should influence clinical decisions (e.g. gly-
caemic control).
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Plain language summary
People living with type 2 diabetes
often have multiple other long-term
conditions (multimorbidity) or
increased vulnerability to aging-
related declines in health (frailty).
These states are common in older
people, however their prevalence and
impact in people aged under 65 years
are less clear. This study uses data
from UK Biobank, a large group of
people aged 40–72 years old, to
study the impact of frailty and mul-
timorbidity in relatively younger
people with type 2 diabetes. We
found that both frailty and multi-
morbidity were common in people
with type 2 diabetes, even at rela-
tively younger ages. People living
with frailty or multimorbidity were at
greater risk of mortality, heart attacks
or strokes, falls or fractures, and of
being hospitalized with low blood
sugar. Assessing frailty and multi-
morbidity may help to identify people
requiring individualized clinical man-
agement and assessment of risk.









Type 2 diabetes mellitus is increasingly common, with pre-valence rising with age1. Aging populations across theworld present a growing challenge for the management of
diabetes2. Type 2 diabetes is associated with states linked to the
aging process3,4, such as frailty and multimorbidity3,5. While the
majority of people living with frailty are aged over 65 years (with
prevalence rising steeply above this age), both frailty and multi-
morbidity are also often present in ‘middle-aged’ people with type
2 diabetes5,6. However, the clinical implications of these concepts
in younger people are less well understood.
Frailty and multimorbidity are related but distinct concepts7.
Neither has a universally accepted definition8,9. Frailty describes a
dynamic state of increased vulnerability to decompensation in
response to physiological stress, characterized by the reduced
physiological reserve10. The two most common definitions are the
frailty phenotype11 and the frailty index12. Multimorbidity refers
to the presence of two or more long-term conditions (LTCs)
within an individual8. Multimorbidity is often quantified using a
count of conditions, sometimes weighted depending on nature or
severity8. Counts vary, however, in the number and type of
conditions included. In both frailty and multimorbidity, the
choice of definition dictates which individuals are identified as
frail or multimorbid, and the degree of overlap between defini-
tions is variable.
Guidelines for type 2 diabetes are beginning to recognize the
importance of identifying frailty in older people with type 2
diabetes and tailoring management accordingly13,14. Specifically,
targets for HbA1c should be relaxed in people with frailty or
multimorbidity13. The rationale for less stringent targets in this
context includes shorter life expectancy, as well as increased
vulnerability to serious adverse effects of hypoglycaemia15.
However, guidelines do not offer tailored guidance as to what
degree of multimorbidity or frailty may alter the balance of risks
and benefits in favour of more relaxed glycaemic targets, or
indeed what conditions should be included in an assessment of
multimorbidity. Importantly, it is not clear if the recommenda-
tions around glycaemic targets hold for younger people with type
2 diabetes who meet the definition of frailty or have
multimorbidity5,6.
To address this evidence gap, this study aims, in UK Biobank
participants aged 40–72 with type 2 diabetes, to: (i) describe the
prevalence of both multimorbidity and frailty using a range of
possible definitions; (ii) assess the overlap between each defini-
tion of multimorbidity and frailty; (iii) compare the association
between multimorbidity/frailty and adverse outcomes; and (iv)
quantify the association between glycaemia (HbA1c) and adverse
outcomes in people with and without frailty/multimorbidity.
We show that both frailty and multimorbidity are common in
middle-aged people with type 2 diabetes, although different
measures of each construct identify different individuals. We also
show that, regardless of the measure used, frailty and multi-
morbidity are both associated with increased risk of mortality,
major adverse cardiovascular events, falls or fractures, and
hypoglycaemia. However, at a given level of frailty or multi-
morbidity, the absolute risk of each of these outcomes is higher
among older people.
Methods
Study population. This is an analysis of UK Biobank participants
with type 2 diabetes. Participants were recruited between
2006–2010 by postal invitation and attended one of 22 assessment
centers in England, Scotland, or Wales where they completed a
touchscreen questionnaire, a nurse interview, had physical mea-
surements, and provided blood samples. Participants also con-
sented to data linkage to healthcare records including mortality
and hospital episode statistics. Participants with type 2 diabetes
were identified according to the validated algorithm developed by
Eastwood et al.16. The UK Biobank has full ethical approval from
the NHS National Research Ethics Service (16/NW/0274). All
participants gave informed consent for participation in UK Bio-
bank. Permission to access and analyse UK Biobank data was
approved under UK Biobank project 14151.
Measures: multimorbidity. For this analysis, we compared two
measures of multimorbidity: the Charlson Comorbidity Index17,
and a numerical count of long-term conditions18. For each score
we removed diabetes, as type 2 diabetes is the index condition for
the analysis. We chose the Charlson Comorbidity Index as it was
recommended in a recent systematic review as the best tool to
assess the risk of mortality in younger populations19. We also
included a numerical count of LTCs, as this is a commonly used
alternative to a weighted score8,20. Conditions were identified
from self-report or from ICD-10 codes from hospital admission
prior to baseline (code lists are detailed in supplementary data
files 1 and 2).
The simple count was based on a list of 42 long-term
conditions originally developed in a large epidemiological study
in Scotland and subsequently adapted for UK Biobank. Condi-
tions were identified based on either self-report or on ICD-10
codes from linked hospital episode statistics. Participants were
considered to have a condition at baseline if they either reported
the condition at the assessment centre nurse interview, or if they
had a hospital admission prior to the assessment centre date with
a relevant ICD-10 diagnostic code (see supplementary data 2 for
relevant ICD-10 codes and self-reported condition included in
each definition). The total number of conditions at baseline was
summed to give an overall count.
Conditions included in the Carlson Comorbidity Index were
similarly identified from self-report or from ICD-10 codes from
hospital admission prior to baseline. ICD-10 codes were taken
from a previously validated algorithm for administrative data.
Each condition was then weighted (ranging from 1–6) according
to the algorithm and the weights were summed to give a
total score.
Measures: frailty. We assessed two operational measures of
frailty at baseline: the frailty phenotype11 and the frailty index12.
These have both been adapted for use in UK Biobank6,21.
The frailty phenotype was based on five criteria (low hand-grip
strength, slow walking speed, weight loss, self-reported exhaus-
tion, and low physical activity) and categorized as robust (0
criteria), pre-frail (1–2 criteria), and frail ( 3 criteria)6,11.
Definitions were adapted to UK Biobank baseline data from the
original description where required. Weight loss was self-reported
according to the question “Compared with one year ago, has your
weight changed?” (yes, reduced= 1, other response= 0). Exhaus-
tion was assess using the question “Over the past two weeks, how
often have you felt tired or had little energy?” (more than half the
days or nearly every day= 1, other= 0). Slow walking pace was
self-reported as “How would you describe your usual walking
pace?” (slow= 1, other= 0). Physical activity was self-reported
according to UK Biobank physical activity questionnaire. We
classified the responses into: none (no physical activity in the last
4 weeks), low (light DIY activity [eg, pruning, watering the lawn]
only in the past 4 weeks), medium (heavy DIY activity [eg,
weeding, lawn mowing, carpentry and digging], walking for
pleasure, or other exercises in the past 4 weeks), and high
(strenuous sports in the past 4 weeks). Participants reporting
none or light activity with a frequency of once per week or less
were coded as ‘low physical activity’. Grip strength was assessed
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using a Jamar J00105 hydraulic hand dynamometer. The highest
valid reading was used to classify grip strength according to cut-
offs described by Fried et al.11.
The frailty index is an unweighted count of ‘deficits’ which (i)
increase in prevalence with age; (ii) are associated with poor
health; and (iii) are neither ubiquitous in the population nor too
rare (i.e. <1% prevalence)12,22. Deficits include long-term
conditions, symptoms, and functional limitations. We used the
list of deficits developed by Williams et al. for UK Biobank
(excluding diabetes)21. This is summarized in supplementary
data 3. The frailty index is calculated by dividing the number of
deficits present by the total number of possible deficits, giving a
value between 0 and 1 (higher values indicating a greater degree
of frailty). Where an individual had missing data for a deficit, this
deficit was also excluded from the demoninator22.
Measures: covariates. All covariates used in analyses were based
on baseline assessment centre data. Age and sex were used as
recorded. BMI was calculated based on measured weight and
height. Smoking was categorized as never, previous, or current
based on self-report. The frequency of self-reported alcohol intake
was categorized as never/special occasions only; 1–3 times per
month, 1–4 times per week, and daily or almost daily. Townsend
scores were calculated from postcode areas based on previous
census data to give an area-based measure of socioeconomic
deprivation23. HbA1c was taken from baseline blood samples
obtained by UK Biobank.
Outcomes. Outcomes were identified by linkage to national
mortality records (Office for National Statistics) and Hospital
Episode Statistics. Linkage was carried out by UK Biobank and
made available to approved researchers. The median follow-up
was 8 years. Outcomes were all-cause mortality, cardiovascular
mortality (the underlying cause of death ICD-10 code beginning
with “I”), cancer mortality (ICD-10 code beginning with “C”),
Major Adverse Cardiovascular Event (MACE; cardiovascular
death, or hospitalisations coded as non-fatal myocardial infarc-
tion [I21] or stroke [I63–I64]), hospitalization with hypoglycae-
mia (E16.0, E16.1, E16.2), and hospitalization with fall or fracture
(W0, W1, S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, T05).
Statistical analysis. We plotted the distribution of each frailty
and multimorbidity measure descriptively. We then summarized
the relationship between each measure and baseline character-
istics by dividing each measure into four quartiles.
To assess the overlap between the four measures of frailty or
multimorbidity we took all participants with scores above the
75th centile for each score (or the ‘frail’ category for the frailty
phenotype). We then constructed a Venn diagram of the overlap
between people above the 75th centile (or “frail” by frailty
phenotype) for each measure.
To assess the relationship between each measure and clinical
outcomes we used parametric survival models. We used Weibull
models as this distribution was found to fit the data well for each
measure and other covariates (assessed by plotting log time
against the log of the estimated cumulative hazard). Models were
adjusted for age, sex, ethnicity, socioeconomic status, BMI,
smoking, and alcohol frequency. We modelled nonlinear effects
of the frailty index, Charlson index, multimorbidity count, and
age using fractional polynomials. We also assessed interactions
between each measure and age, and between age and sex, and
included these in the model where they were significant (p-
interaction < 0.05). We modelled time to the first event.
Competing risks were accounted for by using cause-specific
models (i.e. participants were censored at the first occurrence of
the outcome of interest, end of follow-up, or death, whichever
occurred first. In models for MACE, falls or hypoglycaemia,
deaths of other causes were coded as ‘0’).
After fitting each model we predicted the 5-year risk of the
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Fig. 1 Distribution of frailty or multimorbidity. This figure shows the distribution of each measure of frailty or multimorbidity (panel (a) frailty index, (b)
frailty phenotype, (c) Charlson index, (d) long-term condition count). The height of the bar indicates the number of participants with percentages indicated
above the bars.
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males and females, holding age, BMI and socioeconomic status at
the sample mean, smoking status as ‘previous’ and alcohol
frequency as 1–4 times per week (the most numerous category).
Finally, to assess the impact of HbA1c on all-cause mortality at
different levels of frailty or multimorbidity, we fitted Weibull
models including HbA1c along with the covariates described
above. Non-linear relationships between HbA1c and mortality
were modelled using fractional polynomials. We included any
significant interactions between HbA1c and frailty or multi-
morbidity. The predicted 5-year risk was calculated across all
observed values of HbA1c, and at the 25, 50, 75, and 90th centiles
of each frailty or multimorbidity definition (or at each category of
the frailty phenotype). This allowed us to assess the relationship
between HbA1c and mortality at different levels of multi-
morbidity or frailty.
All analyses were prespecified and reported according to the
Strengthening Reporting of Observational Studies in Epidemiol-
ogy (STROBE) statement (www.strobe-statement.org). Analyses
were performed using R version 3.6.1. All syntax for deriving
variables and for generating analysis will be returned to UK
Biobank for record and will be available upon application to UK
Biobank.
Results
Baseline characteristics. A total of 20,566 UK Biobank partici-
pants were identified as having type 2 diabetes at baseline. The
distribution of multimorbidity (defined by the Charlson
Comorbidity Index and by a count of 42 long-term conditions)
and frailty (defined by the frailty index and by the frailty phe-
notype) is shown in Fig. 1. Baseline characteristics and correlation
between each of these measures are shown in the supplementary
data files 4 and 5 and supplementary Fig. 1.
Most participants with type 2 diabetes were aged over 60 years
(12,755, 62%). Only 1858 (9%) were aged under 50 years. The
prevalence of frailty was broadly similar across age categories (e.g.
frailty prevalence by frailty phenotype was 12.6% at age 40–50,
13.4% at age 50–60, and 11.5% at age 60–72; details in
supplementary tables 1–4). The relationship with age varied
between the individual components of the frailty phenotype. Low
grip strength and slow walking speed increased in prevalence with
increasing age, however low physical activity, self-reported
exhaustion, and self-reported weight loss were more common
in younger participants. However, the prevalence of multi-
morbidity with either measure rose with age (e.g. using the
Charlson Comorbidity Index 7.7% scored ≥ 2 at age 40–50, 11.6%
aged 50–60, and 20.6% aged 60–72).
The relationship between frailty and ethnicity differed depending
on the frailty definition: compared to White participants, frailty is
more common among Black and Asian participants when using the
frailty phenotype definition, but less common when using the frailty
index definition. Multimorbidity was less common among Black or
Asian participants, compared to White. Both frailty and multi-
morbidity were strongly associated with socioeconomic deprivation
by all definitions. Frailty phenotype (but not frailty index) were
associated with slightly higher HbA1c. Participants with multi-
morbidity (using LTC count or Charlson) had lower mean HbA1c.
However, in all cases, the differences were small (<2mmol/mol)
(supplementary data 4 and 5).
Overlap between definitions. There was relatively little overlap
between the four measures of frailty or multimorbidity. Forty-two
percent of participants were above the 75th percentile for at least
one of the measures, but only 2.2% were identified by all 4
measures (Fig. 2). The correlation between measures is shown in
Supplementary Fig. 1.
Relationship between frailty or multimorbidity and outcomes
Mortality. Fig. 3 shows the adjusted 5-year mortality at different
levels of frailty/multimorbidity. Higher degrees of frailty or
multimorbidity were associated with greater all-cause mortality
using each measure. The absolute mortality risk was higher at the
extremes of the multimorbidity count and Charlson Index than
for the frailty phenotype or frailty index, however there were also
fewer participants with values at these extremes. Males had a
higher mortality risk than females.
Age was a significant predictor of mortality risk, independent
of frailty or multimorbidity. For example, using the frailty
phenotype, the 5-year mortality for frailty was 1.9%, 4.4%, and
9.9% in men aged, 45, 55, and 65, respectively. For a
multimorbidity count of 4, predicted 5-year mortality was 1.3%,
3.7%, and 7.8% in med aged 45, 55, and 65, respectively
(supplementary data 6). There was no statistically significant
interaction between age and any measure. Therefore, although the
increase in relative risk associated with frailty or multimorbidity
is similar across all ages studied, the absolute risk of mortality
associated with any level of frailty or multimorbidity is higher at
older ages.
These patterns were similar for cardiovascular mortality and
for cancer mortality (supplementary data 6).
In post-hoc analyses, we assessed the relationship between the
frailty phenotype and mortality within strata of multimorbidity
(0, 1, 2, and 3 or more long-term conditions). At each level of
multimorbidity, frailty was associated with an increased risk of
mortality. Participants meeting the criteria for both frailty and
multimorbidity had a greater risk of mortality than those meeting
the criteria for frailty or multimorbidity alone.
MACE, falls, and hypoglycaemia. The estimated 5-year risk of
incident hospital episode related to MACE, fall/fracture, or
hypoglycaemia, are shown in Fig. 4. Each of these outcomes was
associated with both frailty and multimorbidity. Female partici-
pants were at greater risk of falls/fractures. Males had a higher
risk of MACE and hypoglycaemic hospitalization. As with mor-
tality, the risk was highest at the extreme end of the distributions
for the frailty index, multimorbidity count, and Charlson Index.
Age was also a significant predictor of each outcome, with higher
absolute risks among older participants at a given level of frailty
or multimorbidity (supplementary data 6).
HbA1c and all-cause mortality. Fig. 5 presents the relationship
between HbA1c and all-cause mortality at different levels of
frailty or multimorbidity. Results were stratified according to
centiles (25th, 50th, 75th, and 90th) of each measure, and cate-
gories of the frailty phenotype. The expected J-shaped relation-
ship with mortality was observed throughout all levels apart from
frail participants identified using the frailty phenotype, in whom
the risk of mortality increased in a more linear fashion with
increasing HbA1c. These analyses were repeated after stratifying
by baseline use of drugs associated with hypoglycaemia (insulin
and sulphonylureas). In participants who were frail according to
the frailty phenotype, the steep rise in mortality risk with HbA1c
was only observed in those not taking insulin or sulphonylureas
at baseline. In participants taking these hypoglycaemic agents, the
relationship between HbA1c and mortality was J-shaped for
participants with frailty, as it was for pre-frail and robust parti-
cipants (Supplementary Fig. 2).
Discussion
Both frailty and multimorbidity were common at all ages in this
cohort of 20,566 people with type 2 diabetes aged 40–72 years.
Both the frailty phenotype and frailty index, as well as both
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weighted and unweighted measures of multimorbidity, identified
people at greater risk of mortality as well as MACE and hospital
admission resulting from falls, fractures, or hypoglycaemia.
However, despite similarities in the risks associated with each
measure, the participants who were identified as ‘high risk’ dif-
fered considerably between measures. Therefore, even in this
relatively young population, frailty and multimorbidity identify
people with type 2 diabetes at risk of a wide range of adverse
outcomes, however relying on a single narrow construct may
overlook others who may also be at higher risk.
Guidelines recommend higher glycaemic targets in people with
frailty or substantial multimorbidity13. The higher mortality and
risk of falls and hypoglycaemia that we observed in people with
frailty or multimorbidity are consistent with the rationale for
these higher targets: namely reduced life expectancy and greater
risk of complications of hypoglycaemia15. However, our findings
also demonstrate that the absolute risk of mortality in younger
people with frailty or multimorbidity is considerably lower than
in older people. Furthermore, the risk of all cause mortality
among people identified as ‘frail’ using the frailty phenotype was
highest among people with higher baseline HbA1c. This suggests
that the implications of frailty or multimorbidity for clinical
decision-making must rely on careful consideration of additional
factors that influence baseline risk (including age) as well as
individual patient preferences. This is important, as our findings
suggest that frailty and multimorbidity are common among
people with diabetes under the age of 65, however absolute risk of
outcomes, and thus implications for clinical management, may
differ at younger ages.
It is perhaps surprising that the prevalence of frailty, particu-
larly using the frailty phenotype, did not increase with age. This
was largely driven by a higher prevalence of low physical activity,
self-reported exhaustion, and self-reported weight loss among
younger participants. This could reflect a lack of specificity for
these constructs in identifying frailty when applied to younger
people, in whom characteristics such as exhaustion or weight loss
may be biologically or phenotypically different from older people.
It is important to note, also, that weight loss was not specified as
unintentional in UK Biobank, limiting its specificity for indicating
frailty. Finally, this relationship between frailty and age in this
study could represent collider bias. For example, low physical
activity in may have a causal relationship with the manifestation
of type 2 diabetes at younger ages, but also with the identification
of frailty, thus influencing the relationship between frailty and age
when conditioning on a diagnosis of type 2 diabetes.
The finding that frailty and multimorbidity are common
among middle-aged and older people with type 2 diabetes is
consistent with previous studies5,24. So too is the increased risk of
mortality and cardiovascular events4,24. The finding that the
populations identified by each measure did not fully overlap is
consistent with previous literature and is not surprising, given
that these are distinct constructs underpinned by different models
of frailty or multimorbidity25. Our findings add to this literature
by demonstrating that even in this relatively young population,
each measure identifies individuals at increased risk of adverse
outcomes. Therefore, a narrow focus on a single measure may
overlook others who are also at risk. Individualised person-



















Fig. 2 Venn diagram of overlap between frailty and multimorbidity measures. This figure shows the overlap between each definition of frailty or
multimorbidity. The percentage of participants identified by each combination of measures is shown by the percentages in each overlapping section. Note
that 58% of participants were below the 75th centile for all definitions and are therefore not included in the Venn diagram.
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Fig. 3 Relationship between frailty or multimorbidity and all-cause mortality. This figure shows the predicted 5-year mortality rate for each measure of
frailty or multimorbidity (panel (a) frailty index, (b) frailty phenotype, (c) Charlson index, (d) long-term condition count). Coloured lines or points indicate
point estimates for predicted 5-year mortality. Men are shown in blue, and women in red. Shaded areas indicate 95% confidence intervals. Grey circles
indicate the number of participants with each level of frailty or multimorbidity. Models are adjusted for age, sex, socioeconomic status, body mass index,
smoking, and alcohol. Predicted 5-year mortality is based on age 60, socioeconomic status and body mass index held at the sample mean, previous
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Fig. 4 Relationship between frailty or multimorbidity and MACE, hypoglycaemia, and falls. This figure shows the predicted 5-year rate of fall or fracture
(panels a, b, c, and d showing the frailty index, frailty phenotype, Charlson index, and long-term condition count, respectively) hospitalization with
hypoglycaemia (panels e, f, g, and h showing the frailty index, frailty phenotype, Charlson index, and long-term condition count, respectively) and MACE
(panels i, j, k and m showing the frailty index, frailty phenotype, Charlson index, and long-term condition count, respectively). Coloured lines or points
indicate point estimates for predicted 5-year mortality. Men are shown in blue, and women in red. Shaded areas indicate 95% confidence intervals. Models
are adjusted for age, sex, socioeconomic status, body mass index, smoking, and alcohol. Predicted 5-year risk is based on age 60, socioeconomic status
and body mass index held at the sample mean, previous smokers, and 1–4 times weekly alcohol intake.
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of measure and further research, ideally using randomised trials,
is required to understand if and how our approach should differ
by how frailty or multimorbidity manifests.
The small magnitude of difference in HbA1c with frailty or
multimorbidity identified is consistent with existing literature, the
majority of which have shown no association with HbA1c4,24,26.
This is perhaps surprising given guidelines for lower targets. Our
findings may reflect the relatively young age of this cohort.
However, others have observed hypoglycaemic medications are
rarely discontinued in patients with frailty and low HbA1c,
despite the risk of hypoglycaemia that this presents27.
The relationship between HbA1c and mortality in people
classified as ‘frail’ using the frailty phenotype is surprising, as we
had expected the risks associated with lower HbA1c to be higher
in people with frailty. Further analyses stratified by baseline use of
hypoglycaemic agents suggest that low HbA1c in the context of
insulin or sulphonylurea use (potentially reflecting over-treat-
ment) is associated with increased mortality regardless of frailty
status. Patients with low HbA1c may therefore benefit from
deprescribing or dose reduction. The steeper rise in mortality
with higher HbA1c and frailty was mostly driven by participants
not taking these agents and may reflect a greater risk of sub-
optimal glycaemic control in younger people living with frailty.
This finding would need to be verified in other cohorts, and also
explored further in older populations which represent the
majority of people living with frailty.
Few studies have assessed the relationship between frailty and
hypoglycaemia24. Several studies, mostly using the Charlson
comorbidity index, have shown an increased risk of hypogly-
caemia associated with multimorbidity4. Evidence linking frailty
with hypoglycaemia has been based on findings from trials such
as ACCORD where patients over 80 years old had high rates of
hypoglycaemia when randomised to the intervention arm28, as
well as the fact that older people appear most likely to be hos-
pitalised with hypoglycaemic complications29–31. In both cases
frailty has been hypothesized to explain the underlying vulner-
ability. Our findings are concordant with this hypothesis and
suggest that frailty may also confer some increased risk at
younger ages.
Clinicians managing type 2 diabetes are likely to encounter
high levels of frailty and multimorbidity, even among relatively
young patient populations. Guideline recommendations for less
stringent glycaemic targets in people living with frailty are in part
predicated on limited life expectancy13–15. Our findings demon-
strate that both frailty and age are important predictors of mor-
tality risk, and while younger people with type 2 diabetes may
meet the criteria for frailty, their absolute risk of mortality may be
considerably less than an older person identified as frail. Fur-
thermore, the choice of measure for frailty or multimorbidity
substantially impacts which individuals are identified as ‘high
risk’, with only partial overlap between definitions. These obser-
vations, consistent with previous literature, are important in this
context as diabetes guidelines do not currently give recommen-
dations for how frailty in younger people should influence
management (and in whom the assumptions around life expec-
tancy underpinning recommendation for older people are unli-
kely to hold) or how frailty and multimorbidity should be
identified. Within populations identified as frail or multimorbid
there is considerable heterogeneity in personal characteristics as
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Fig. 5 HbA1c and all-cause mortality. This figure shows the relationship between HbA1c and predicted 5-year mortality at different levels of frailty or
multimorbidity (panel (a) frailty index, (b) frailty phenotype, (c) Charlson index, (d) long-term condition count). Coloured lines or points indicate point
estimates for predicted 5-year mortality. Colours indicate the level of frailty or multimorbidity according to centiles. Shaded areas indicate 95% confidence
intervals. Models are adjusted for age, sex, socioeconomic status, body mass index, smoking, and alcohol. Predicted 5-year mortality is based on age 60,
socioeconomic status, and body mass index held at the sample mean, previous smokers, and 1–4 times weekly. There was a significant interaction between
the frailty phenotype and HbA1c. Interactions between frailty index, Charlson index, and LTC count were not significant.
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importance of individualised decision-making for patients, taking
into account patients’ age and the measure used to assess frailty
and multimorbidity, rather than blanket recommendations for
‘frailty’ or ‘multimorbidity’. So, while a recent systematic review
has suggested the need to embed screening for frailty within
routine diabetes reviews24, this work suggests that clinicians need
to ensure care is tailored to the potential needs of people with
frailty or multimorbidity taking into account of a wide range of
factors. While frailty and multimorbidity do indicate gradients of
risk, it may be that these are not the optimal tools to assess the
appropriate targets for treatment in middle-aged people.
The strengths of this study include its large sample size with
linkage to mortality and hospital event data. We also used a range
of definitions of frailty and multimorbidity, which is an advantage
as comparisons between studies are often limited by differences in
the definitions used. Our focus on younger people than most pre-
vious frailty studies is relatively novel, as the implications of frailty
in younger ages are not well understood. However, our findings
may not be entirely transferable to older people (>70 years), in
whom frailty is both more prevalent and may have a greater impact.
UK Biobank was not specifically designed to assess frailty or aging,
which limits our assessment of frailty. Specifically, some of the
frailty phenotype components were adapted (e.g. weight loss was
self-reported and not specifically unintentional) and the frailty
index, while constructed according to standard guidelines, contains
relatively few functional and sensory deficits.
Our analysis was limited by only having access to baseline
measures of frailty and multimorbidity, as well as covariates such
as HbA1c and body mass index. Both frailty and multimorbidity
are dynamic states and change (often progressing) over time. We
were not able to model the impact of any such change. Modelling
of the impact of multimorbidity and frailty in diabetes could
potentially be improved by using serial measurements, over a
longer follow-up, and with measurement of additional outcomes
such as retinopathy and nephropathy. Several of the baseline
variables were based on self-report, however participants were
supported by a study nurse in providing this information and for
the multimorbidity measures we supplemented these definitions
with linkage to previous hospital episodes. Finally, it is important
to note that UK Biobank is not a nationally representative sample.
Participants were more affluent, more likely to be White, and
have fewer long-term health conditions than the national average.
Our prevalence findings therefore cannot be generalized to the
population as a whole, and estimates of the risk of adverse out-
comes are likely to be conservative. Selection bias may also lead to
collider bias, where conditioning on one criteria (UK Biobank
inclusion) may bias estimates of the relationship between causally
proximal variables (such as age and frailty)32,33. This may explain
the surprising finding that the prevalence of the frailty phenotype
did not rise with age as expected26.
In conclusion, our findings demonstrate that both frailty and
multimorbidity are both common and clinically important in
middle-aged as well as older people with type 2 diabetes,
regardless of the definition used. The greater risk of mortality,
cardiovascular events, and hypoglycaemia, in people living with
frailty and multimorbidity means that it is important to actively
detect both frailty and multimorbidity in people with type 2
diabetes, regardless of age. However, our findings also demon-
strate that guidelines for managing frailty and multimorbidity in
people with type 2 diabetes may not be directly applicable to
younger people, in whom the absolute mortality risk remained
low even among the most frail groups. While this work further
supports the idea of embedding screening for both multi-
morbidity and frailty as part of routine diabetes reviews, it also
reinforces the need to tailor risk stratification to individual
patients. This should take account of patients’ age, measure used
to assess frailty or multimorbidity, and other risk factors, rather
than adopting prescriptive targets and recommendations to
everyone who might meet some criteria for frailty or
multimorbidity.
Reporting summary. Further information on research design is
available in the Nature Research Reporting Summary linked to
this article.
Data availability
The UK Biobank data that support the findings of this study are available from the UK
Biobank (www.ukbiobank.ac.uk), subject to approval by UK Biobank. Source data for the
main figures in the manuscript can be accessed as Supplementary Data 7.
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